Search clinical trials for: prior PARP inhibitor exposure

Total 73233 results

Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Zhejiang Cancer Hospital

Active, not recruiting

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

Epithelial Ovarian Cancer

China
Australasian Leukaemia and Lymphoma Group

Recruiting

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. (GOlDiLOX)

Mantle Cell Lymphoma | Mantle Cell Lymphoma Refractory

Australia
AstraZeneca
Merck Sharp & Dohme LLC

Completed

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer

Belgium, France, Italy, Netherlands, Poland, United States, Canada, Czechia, Russian Federation, United Kingdom, Spain
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100

Castration-Resistant Prostate Cancer (CRPC)

United States, Moldova, Republic of, South Africa
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
AbbVie (prior sponsor, Abbott)

Completed

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)

Completed

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Gastric Cancer

United States, Korea, Republic of
Central European Society for Anticancer Drug Research

Unknown

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Small Cell Lung Cancer SCLC

Germany
National Cancer Institute (NCI)

Completed

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Glioblastoma | Brain Neoplasms | Central Nervous System Neoplasms | Glioblastoma Multiforme | Gliosarcoma

United States
National Cancer Institute (NCI)

Terminated

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

Ovarian Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Terminated

Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure

Solid Tumors Induced by Prior Radiation Exposure

United States
AbbVie (prior sponsor, Abbott)

Completed

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Brain Diseases | Central Nervous System Diseases | Neoplasm Metastasis | Brain Neoplasms | Nervous System Neoplasms

United States, Canada, Puerto Rico
AbbVie (prior sponsor, Abbott)
Prostate Cancer Clinical Trials Consortium

Completed

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Prostate Cancer
AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

United States, Australia
AbbVie (prior sponsor, Abbott)

Completed

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Solid Tumors

United States
University of Iowa
National Cancer Institute (NCI)

Terminated

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Multiple Myeloma

United States
British Columbia Cancer Agency

Completed

Biomarker - Panitumumab Response With KRAS Wild Type MCC

Metastatic Colorectal Cancer

Canada
AbbVie (prior sponsor, Abbott)

Completed

A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Non-Small -Cell Lung Cancer
Biosense Webster, Inc.

Completed

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

Paroxysmal Atrial Fibrillation

United States, France, Switzerland
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Metastatic Urothelial Carcinoma | Unresectable Urothelial Carcinoma
Chengdu Baiyu Pharmaceutical Co., Ltd.

Recruiting

A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors

Solid Tumor, Adult

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501)

Advanced Solid Tumor

United States, Germany
University of Kansas Medical Center

Not yet recruiting

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis，MF
M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative | Metastatic Invasive LObular Carcinoma

United States
Children's Oncology Group

Not yet recruiting

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Stage I Kidney Wilms Tumor | Stage II Kidney Wilms Tumor | Stage III Kidney Wilms Tumor | Stage IV Kidney Wilms Tumor
Acerand Therapeutics (Shanghai) Limited

Recruiting

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Solid Tumor, Adult

China
KU Leuven
Utrecht University

Recruiting

Virtual Reality Exposure for Socially Anxious Adolescents (VIRTUS)

Social Anxiety

Belgium
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Children's Oncology Group

Not yet recruiting

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

Central Nervous System Germinoma | Diabetes Insipidus | Pineal Region Germinoma | Suprasellar Germinoma
Ibrahim Halil Sahin
GlaxoSmithKline

Not yet recruiting

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

MMR-D/MSI-H Colorectal Cancers

United States
Beijing Luhe Hospital

Recruiting

Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction

STEMI

China
Northside Hospital, Inc.

Not yet recruiting

Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Fondazione del Piemonte per l'Oncologia

Recruiting

INSIDE: Identification of Genomic Screening Pathways in Cancer Patients With DNA Repair Alterations (INSIDE)

Prostate Cancer

Italy
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Medical College of Wisconsin

Not yet recruiting

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Non Small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Advanced Hepatocellular Carcinoma

China
ANRS, Emerging Infectious Diseases

Not yet recruiting

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France. (CABOPrEP)

Prevention

France
Jinling Hospital, China

Recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Renal Cell Carcinoma | Radiotherapy | Immune Checkpoint Inhibitor

China
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
Africa Health Research Institute

Recruiting

Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT (LAPIS)

HIV Infections

South Africa
Fujian Cancer Hospital
Fujian Provincial Hospital

Not yet recruiting

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Ovarian Neoplasms
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
University Hospital, Caen

Not yet recruiting

Is Ibrutinib-related Atrial Fibrillation Dose Dependent

Atrial Fibrillation | Hematological Malignancy

France
Annemieke Geluk
The Leprosy Mission Bangladesh

Recruiting

Novel Interventions and Diagnostic Tests for Leprosy (INDIGO#2)

Leprosy

Bangladesh
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
Hospital of Macerata

Not yet recruiting

ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa

Prostate Cancer

Italy

3

Subscribe